Manhattan Pharmaceuticals Obesity Drug Safe in Phase Ia Study
7th Sep 2005, 17:51 GMT
Manhattan Pharmaceuticals said Oleoyl-estrone, its experimental obesity drug, was shown safe with no serious adverse events noted in a Phase Ia study of 36 obese volunteers.
Latest news from Financial News News from myHealthcareNews.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris